ILD-SARDs Registry and Biorepository
Recruiting · NCT05007340 · Observational (researchers observe without assigning treatment) · Lead sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
A complex interaction between demographic, environmental and genetic mechanisms impact the onset, severity and outcome of ILD-SARDs through dysregulation of the immune system and lung pro-biotic pathways. Comorbidity and genetic risk indicate that there are overlapping pathogenic mechanisms among SARDs, some of which underlie ILD in different SARDs. The purpose of this biobank is to study the clinical, pathological, laboratory, and imaging characteristics of SARDs patients with lung involvement. This will help identify as unique features underlying lung involvement in SARDs. In addition, this may lead to the discovery of novel mechanisms of disease and potentially novel targets of treatment for SARDs patients with lung disease.
Who can take part
Inclusion criteria
- Must be aged 18 years or older
- Diagnosis of ILD as confirmed by a chest CT
- Either a defined SARD, an undifferentiated connective tissue disease or features of autoimmunity without meeting clinical criteria for SARD
- Patient must be willing to give their informed consent and must be able to understand and follow the required study procedures.
Exclusion criteria
- N/A
Where it is running
1 location listed.
- RI-MUHC - Montreal, Quebec, Canada